ZYME
Zymeworks Inc.
NASDAQ · Healthcare · Biotechnology · CA
$29.19
−2.37%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 37.1M | 106.0M | 76.3M | 76.0M | 412.5M |
| Cost of Revenue | 4.5M | — | — | 143.0M | — |
| Gross Profit | 32.6M | 106.0M | 76.3M | (67.0M) | 412.5M |
| Operating Expenses | |||||
| R&D Expense | 2.5B | 137.0M | 134.6M | 143.6M | 208.6M |
| SG&A Expense | 15.1B | 61.5M | 61.5M | 70.4M | 73.4M |
| General & Admin Expense | 15.1B | 61.5M | 61.5M | 70.4M | 73.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (17.4B) | — | 17.3M | (142.9M) | (42.0K) |
| Total Operating Expenses | 188.1M | 198.5M | 213.4M | 71.1M | 282.0M |
| Cost and Expenses | 192.7M | 198.5M | 213.4M | 214.1M | 282.0M |
| Operating Income (EBIT) | (155.6M) | (92.5M) | (137.1M) | (138.1M) | 130.5M |
| Non-Operating | |||||
| Interest Income | 12.5M | 13.4M | 19.9M | 19.7M | 3.6M |
| Interest Expense | 2.1M | — | — | — | — |
| Net Interest Income | 10.4M | 13.4M | 19.9M | 19.7M | 3.6M |
| Other Non-Op Income/Expense | 4.2M | 12.8M | 20.5M | 18.8M | 4.7M |
| Non-Operating Income (excl Interest) | (6.2M) | (12.8M) | (17.3M) | (46.0K) | 42.0K |
| EBT (Pre-Tax Income) | (151.4M) | (79.8M) | (116.6M) | (119.2M) | 135.2M |
| Income Tax Expense | (1.4M) | 1.4M | 6.1M | (568.0K) | 10.9M |
| Bottom Line | |||||
| Net Income | (150.0M) | (81.1M) | (122.7M) | (118.7M) | 124.3M |
| Earnings from Cont. Ops | (150.0M) | (81.1M) | (122.7M) | (118.7M) | 124.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (150.2M) | (81.3M) | (122.6M) | (118.7M) | 124.1M |
| Per Share | |||||
| Basic EPS | ($2.02) | ($1.08) | ($1.62) | ($1.72) | $1.91 |
| Diluted EPS | ($2.02) | ($1.08) | ($1.62) | ($1.72) | $1.90 |
| Revenue Per Share | $0.51 | $1.41 | $1.01 | $1.10 | $6.33 |
| Shares | |||||
| Basic Shares Outstanding | 73.0M | 75.3M | 75.8M | 68.9M | 65.2M |
| Diluted Shares Outstanding | 73.0M | 75.3M | 75.9M | 68.9M | 65.2M |
| Profitability Metrics | |||||
| EBITDA | (139.9M) | (68.6M) | (108.6M) | (120.7M) | 142.5M |
| D&A | 9.4M | 11.1M | 11.2M | 17.3M | 12.0M |
| EBIT | (149.3M) | (79.8M) | (119.8M) | (138.0M) | 130.5M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026